Should omalizumab be used in severe asthma/COPD overlap?

Sposato, B; Scalese, M; Milanese, M; Masieri, S; Cavaliere, C; Ricci, A; Paggiaro, P

Sposato, B; Scalese, M; Milanese, M; Masieri, S; Cavaliere, C; Ricci, A; Paggiaro, P.

Afiliación

Sposato B; Pneumology Department, Misericordia Hospital, Grosseto, Italy.
Scalese M; Institute of Clinical Physiology, CNR, Pisa, Italy.
Milanese M; Pneumology Department, S. Corona Hospital, Pietra Ligure (SV), Italy.
Masieri S; Otorhinolaryngology Clinic, Policlinico Umberto I, Sapienza University, Rome, Italy.
Cavaliere C; Otorhinolaryngology Clinic, Policlinico Umberto I, Sapienza University, Rome, Italy.
Ricci A; Division of Pneumology, Department of Clinical and Molecular Medicine, Sapienza University of Rome, AOU SantAndrea, Rome, Italy.
Paggiaro P; Cardio Thoracic and Vascular Department, Pathophysiology Unit, University of Pisa, Italy.

J Biol Regul Homeost Agents ; 32(4): 755-761, 2018.

Article en En | MEDLINE | ID: mdl-30043557

Asunto(s)

Antiasmáticos/uso terapéutico; Asma/tratamiento farmacológico; Omalizumab/uso terapéutico; Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico; Asma/complicaciones; Humanos; Enfermedad Pulmonar Obstructiva Crónica/complicaciones

Buscar en Google

Imprimir

XML

PubMed Links

Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Asma / Antiasmáticos / Enfermedad Pulmonar Obstructiva Crónica / Omalizumab Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: J Biol Regul Homeost Agents Asunto de la revista: BIOLOGIA / BIOQUIMICA Año: 2018 Tipo del documento: Article País de afiliación: Italia

Buscar en Google

Imprimir

XML

PubMed Links